Dr. Miron on Resistance Mechanisms to FGFR Inhibitors in Cholangiocarcinoma

Supplements and Featured PublicationsNovel Therapeutic Approaches to Target FGFR Mutations in Solid Tumors
Volume 1
Issue 1

Benjamin Miron, MD, discusses mechanisms of resistance to FGFR inhibitors in cholangiocarcinoma.

Benjamin Miron, MD, fellow, Hematology/Oncology, Fox Chase Cancer Center, discusses mechanisms of resistance to FGFR inhibitors in cholangiocarcinoma.

Treatment with FGFR inhibitors can lead to the emergence of several mutations that promote resistance, Miron says. Although there is not much known about these mutations, data from the use of FGFR inhibitors in biliary cancers have shed some light on some resistance mechanisms, Miron explains. These resistance mutations are similar to those that have been observed with other TKIs, such as EGFR inhibitors, Miron adds.

There are currently no approved agents that can target resistance mechanisms to FGFR inhibitors; however, drugs are under development to fill this unmet need, Miron adds. Without approved drugs, the current standard for patients who develop such mutations during treatment with an FGFR inhibitor is to switch therapies or to enroll to a clinical trial, Miron concludes.

Related Videos
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
C. Ola Landgren, MD, PhD
Timothy Yap, MBBS, PhD, FRCP
Muhamed Baljevic, MD, FACP
Kathleen A. Dorritie, MD
David L. Porter, MD, director, Cell Therapy and Transplant, Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Penn Medicine
Muhamed Baljevic, MD